Cubist Systematic Strategies LLC Increases Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Cubist Systematic Strategies LLC lifted its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 302.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 98,383 shares of the biotechnology company’s stock after purchasing an additional 73,923 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.13% of CytomX Therapeutics worth $101,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in shares of CytomX Therapeutics by 288,736.3% during the 4th quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company’s stock worth $836,000 after acquiring an additional 811,349 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of CytomX Therapeutics by 32.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company’s stock worth $1,387,000 after acquiring an additional 331,800 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 27,800 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in shares of CytomX Therapeutics by 13.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company’s stock worth $1,422,000 after acquiring an additional 169,000 shares during the last quarter. Finally, Algert Global LLC bought a new stake in shares of CytomX Therapeutics during the 4th quarter worth approximately $35,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th. HC Wainwright raised CytomX Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Thursday, May 15th. Piper Sandler lifted their target price on CytomX Therapeutics from $2.50 to $5.00 and gave the company an “overweight” rating in a research report on Thursday, May 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $6.00 target price (up from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th.

CytomX Therapeutics Stock Up 4.9%

Shares of NASDAQ CTMX opened at $2.13 on Tuesday. The business has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $0.90. The firm has a market cap of $171.72 million, a PE ratio of 12.53 and a beta of 1.11. CytomX Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $2.55.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The business had revenue of $50.92 million during the quarter, compared to analyst estimates of $35.42 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the company posted $0.17 EPS. On average, research analysts expect that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.